Allstocks.com's Bulletin Board
Topic Closed  Topic Closed
Post New Topic  New Poll  
Topic Closed  Topic Closed
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » PLRS - Patent issuance? (.0001)

 - UBBFriend: Email this page to someone!    
Author Topic: PLRS - Patent issuance? (.0001)
OO7
Member


Rate Member
Icon 1 posted      Profile for OO7     Send New Private Message       Edit/Delete Post 
Kinda confused about this one, Is a Patent issuance the same as recieving a patent for something? It seems to me That usually When ever a stock get a medical patent they should fly.
Any thought or comment from someone in the know would be appreciated. thanks Joel

PLRS Pluristem Obtains Issuance from U.S. Patent Office for Coverage of Proprietary Stem Cell Expansion Technology
Business Wire - October 6, 2005 7:30 AM (EDT)

Company Simulates Natural Environment of Human Bone to Expand Hematopoietic Stem Cells, Without Growth Factors, Initially Targeting Bone Marrow Transplantation Market Exceeding $5 Billion

HAIFA, Israel, Oct 06, 2005 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (OTC BB: PLRS), a biotechnology company dedicated to the expansion of stem cells from umbilical cord blood to address a myriad of fatal illnesses, today announced that it received an Issuance from the U.S. Patent Office for "Method of Producing Undifferentiated Hematopoietic Stem Cells Using a Stationary Phase Plug Flow Bioreactor" - U.S. Patent Number 6911201. The Company also holds issued patents in Australia, New Zealand and South Africa.

The patent allowance provides coverage to Pluristem's concept of creating a three-dimensional bone-like environment that supports expansion of hematopoietic stem cell form cord blood samples while minimizing their differentiation into more mature cells that cannot be transplanted into the patient and reconstituted his blood and immune system.

Additionally, the patent issuance protects the concept and the mechanism of action of the PluriX(TM) bioreactor. Two key features differentiate Pluristem's system from the surrounding competition. First, unlike the two-dimensional conditions and the suspension cultures utilized by most competitors, Pluristem's technology mimics the three-dimensional (3-D) natural bone marrow environment. Second, the expansion process is carried out in an environment not supplemented with exogenous, potential biohazard growth factors.

Pluristem's core technology is designed to expand Hematopoietic Stem Cells (HSC). These cells are required for bone marrow transplants and are the only cells that can reconstitute a critically damaged hematopoietic system. In the physiologic environment simulated within the PluriX(TM) bioreactor, these life saving stem cells can self-renew and expand while concomitant differentiation processes are minimized. Reducing differentiation rate of hematopoietic stem cell is critical to the validity of any expansion technology as differentiated cells cannot repopulate and rebuild a patient's hematopoietic (blood and immune) system. Additionally, our expansion protocol makes use of cord blood rather than traditionally used bone marrow. Cord blood is preferred over bone marrow as a source of stem cells for many reasons including absence of morbidity to the donor and less demanding tissue match for the recipient.

"Issuance of this patent at this crucial phase in time has allowed Pluristem to be in a key position in this enormous market. The 3-D human marrow-like environment created in the PluriX(TM) bioreactor has enormous potential. This clearly revolutionizes the field of bone marrow transplantation and can potentially eliminate the suffering associated with the toxic side effects of traditional therapies," stated Dr Shai Meretzki, CTO and co-inventor of Pluristem's stem cell expansion technology.

"Pluristem is well positioned, with this broad patent protection, to actively pursue partnering relationships, to garner significant market share due to the strength of the patent issuance, and communicate its renaissance to the investment community. The issuance of this patent strengthens our belief that the PluriX(TM) cell expansion system is a promising solution for the critical global shortfall of matched tissue for bone marrow transplantation (BMT). The ability of Pluristem's technology to expand HSCs in a non-supplemented cytokine environment is to our knowledge unique and has the potential to save millions of lives," added Zami Aberman CEO.

Posts: 238 | From: Us | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
OO7
Member


Rate Member
Icon 1 posted      Profile for OO7     Send New Private Message       Edit/Delete Post 
correction Stock opened at .142 now at .20 63%
looking great!!!!

Posts: 238 | From: Us | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
   

Post New Topic  New Poll  
Topic Closed  Topic Closed
Open Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share